132 related articles for article (PubMed ID: 37080373)
41. Impact of
Al-Ibraheem A; Hirmas N; Fanti S; Paez D; Abuhijla F; Al-Rimawi D; Al-Rasheed U; Abdeljalil R; Hawari F; Alrabi K; Mansour A
BMC Med Imaging; 2021 Mar; 21(1):49. PubMed ID: 33731050
[TBL] [Abstract][Full Text] [Related]
42. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
43. A SUV
Ye L; Xu F; Shi S; Zeng Z; Jin X; Huang Y; Lu C; Gu J; Ge D; He J
Clin Transl Oncol; 2018 Aug; 20(8):1026-1034. PubMed ID: 29327241
[TBL] [Abstract][Full Text] [Related]
44. Maximum standardized uptake value on FDG-PET is a strong predictor of overall and disease-free survival for non-small-cell lung cancer patients after stereotactic body radiotherapy.
Takeda A; Sanuki N; Fujii H; Yokosuka N; Nishimura S; Aoki Y; Oku Y; Ozawa Y; Kunieda E
J Thorac Oncol; 2014 Jan; 9(1):65-73. PubMed ID: 24346094
[TBL] [Abstract][Full Text] [Related]
45. Tumour standardized uptake value on positron emission tomography is a novel predictor of adenocarcinoma in situ for c-Stage IA lung cancer patients with a part-solid nodule on thin-section computed tomography scan.
Hattori A; Suzuki K; Matsunaga T; Fukui M; Tsushima Y; Takamochi K; Oh S
Interact Cardiovasc Thorac Surg; 2014 Mar; 18(3):329-34. PubMed ID: 24351509
[TBL] [Abstract][Full Text] [Related]
46. Pretreatment maximum standardized uptake value on 18F-fluorodeoxyglucose positron emission tomography is a predictor of outcome for stage I non-small cell lung cancer after stereotactic body radiotherapy.
Tanaka H; Hayashi S; Hoshi H
Asia Pac J Clin Oncol; 2016 Mar; 12(1):e113-7. PubMed ID: 24176011
[TBL] [Abstract][Full Text] [Related]
47. Long-Term Results for Clinical Stage IA Lung Cancer: Comparing Lobectomy and Sublobar Resection.
Subramanian M; McMurry T; Meyers BF; Puri V; Kozower BD
Ann Thorac Surg; 2018 Aug; 106(2):375-381. PubMed ID: 29580779
[TBL] [Abstract][Full Text] [Related]
48. Timing of fluorodeoxyglucose positron emission tomography maximum standardized uptake value for diagnosis of local recurrence of non-small cell lung cancer after stereotactic body radiation therapy.
Tan D; Gill S; Loh N
Cancer Med; 2020 Oct; 9(20):7469-7476. PubMed ID: 32846054
[TBL] [Abstract][Full Text] [Related]
49. Comparison of prognostic values of primary tumor and nodal
Lim CH; Hyun SH; Moon SH; Cho YS; Choi JY; Lee KH
Eur Radiol; 2019 Oct; 29(10):5288-5297. PubMed ID: 30899978
[TBL] [Abstract][Full Text] [Related]
50. Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy.
Zhao K; Wang C; Shi F; Huang Y; Ma L; Li M; Song Y
BMC Cancer; 2021 Jan; 21(1):66. PubMed ID: 33446134
[TBL] [Abstract][Full Text] [Related]
51. Are discordant positron emission tomography and pathological assessments of the mediastinum in non-small cell lung cancer significant?
Tandberg DJ; Gee NG; Chino JP; D'Amico TA; Ready NE; Coleman RE; Kelsey CR
J Thorac Cardiovasc Surg; 2013 Oct; 146(4):796-801. PubMed ID: 23870158
[TBL] [Abstract][Full Text] [Related]
52. Prognostic impact of FDG-PET in surgically treated pathological stage I lung adenocarcinoma.
Higuchi M; Hasegawa T; Osugi J; Suzuki H; Gotoh M
Ann Thorac Cardiovasc Surg; 2014; 20(3):185-91. PubMed ID: 23603641
[TBL] [Abstract][Full Text] [Related]
53. Is FDG-PET/CT used correctly in the combined approach for nodal staging in NSCLC patients?
Simsek FS; Comak A; Asik M; Kuslu D; Balci TA; Ulutas H; Koroglu R; Kekilli E; Akatli A; Elmali F; Yalcin NC; Akyol H
Niger J Clin Pract; 2020 Jun; 23(6):842-847. PubMed ID: 32525121
[TBL] [Abstract][Full Text] [Related]
54. New positron emission tomography derived parameters as predictive factors for recurrence in resected stage I non-small cell lung cancer.
Melloni G; Gajate AM; Sestini S; Gallivanone F; Bandiera A; Landoni C; Muriana P; Gianolli L; Zannini P
Eur J Surg Oncol; 2013 Nov; 39(11):1254-61. PubMed ID: 23948705
[TBL] [Abstract][Full Text] [Related]
55. Formula corrected maximal standardized uptake value in FDG-PET for partial volume effect and motion artifact is not a prognostic factor in stage I non-small cell lung cancer treated with stereotactic body radiotherapy.
Yamamoto T; Kadoya N; Shirata Y; Kaneta T; Koto M; Umezawa R; Ishikawa Y; Kubozono M; Sugawara T; Matsushita H; Abe K; Takeda K; Jingu K
Ann Nucl Med; 2015 Oct; 29(8):666-73. PubMed ID: 26040413
[TBL] [Abstract][Full Text] [Related]
56. The value of different
Anwar H; Vogl TJ; Abougabal MA; Grünwald F; Kleine P; Elrefaie S; Nour-Eldin NA
Ann Nucl Med; 2018 Dec; 32(10):687-694. PubMed ID: 30219989
[TBL] [Abstract][Full Text] [Related]
57. Association of circulating tumour cells with early relapse and 18F-fluorodeoxyglucose positron emission tomography uptake in resected non-small-cell lung cancers.
Bayarri-Lara CI; de Miguel Pérez D; Cueto Ladrón de Guevara A; Rodriguez Fernández A; Puche JL; Sánchez-Palencia Ramos A; Ruiz Zafra J; Giraldo Ospina CF; Delgado-Rodríguez M; Expósito Ruiz M; Moyano Rodriguez MJ; Lorente JA; Serrano MJ
Eur J Cardiothorac Surg; 2017 Jul; 52(1):55-62. PubMed ID: 28369376
[TBL] [Abstract][Full Text] [Related]
58. SUVmax during 18FDG-PET scanning in small cell lung cancer: similar information as in non-small cell lung cancer?
van der Leest C; Smit EF; Baas J; Versteijlen RJ; van Walree N; Hoogsteden HC; Aerts JG
Lung Cancer; 2012 Apr; 76(1):67-71. PubMed ID: 21996089
[TBL] [Abstract][Full Text] [Related]
59. Limitations of 18F-2-deoxy-D-glucose positron emission tomography in N1 detection in patients with pathologic stage II-N1 and implications for management.
Kim MP; Correa AM; Hofstetter W; Mehran R; Rice DC; Roth JA; Vaporciyan AA; Walsh GL; Erasmus JJ; Swisher SG
Ann Thorac Surg; 2015 Feb; 99(2):414-20. PubMed ID: 25497068
[TBL] [Abstract][Full Text] [Related]
60. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
